Expect Big Things from Nuvasive
-
Font Size:
NuVasive (NUVA), a developer of surgical spine treatments, will offer $200 million convertible senior notes due 2013. The company estimates that the net proceeds from the offering will be $193.4 million, assuming no exercise of the purchasers’ over-allotment option of up to $30 million of additional notes.
NuVasive intends to use the net proceeds from the offering for “general corporate purposes, including potential strategic acquisitions”.
The notes will pay interest semiannually at a rate of 2.25% per annum and will be convertible into shares of NuVasive common stock at a conversion price of approximately $44.74 per share. The offering is scheduled to close on March 7, 2008.
NuVasive’s
principal product is the minimally disruptive Maximum Access Surgery
(MAS) platform. MAS is comprised of three components: Neurovision, a
proprietary software-driven nerve avoidance system; MaXcess, a
split-blade design retraction system; and specialized implants, like
SpheRx and CoRoent which collectively minimize soft tissue disruption
during spine surgery while allowing maximum visualization and surgical
reproducibility.
The MAS platform continues to rule the company’s balance sheet. The system offers significant advantages to both patients and surgeons, including reduced hospitalization time and faster recovery. NuVasive has a state-of-the art cadaver operating theater and training facilities focused on educating leading surgeons on the advantages of NuVasive products.
The company has been growing rapidly over the past several years, buoyed by successful execution of general corporate strategy, the launch of new products, strategic acquisitions and the transition to an in-house sales team.
In the third quarter of 2006, the NuVasive completed an accelerated buyout agreement with Pearsalls Limited related to the NeoDisc investigational device and related embroidery technology. In January 2007, NuVasive acquired Radius Medical, a privately-owned developer of biologics used in bone graft and spinal fusion procedures.
- SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial »
- Immtech Pharmaceuticals, Inc. F1Q09 (Qtr End 06/30/08) Earnings Call Transcript »
- Five Biopharma Companies Drop on Negative Drug News »
- Amylin, Lilly: Another Case of a Panic Driven Sell-Off »
- Drug Safety Updates For Elan, Biogen, Amylin, and Lilly »
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
ETFs In Focus
-
Editor's Picks
-
Most Popular
- Latest Commodities Indicator: Fed Policy
- Thoughts on Mohamed El-Erian's 'When Markets Collide'
- Priceline: More Headwinds Ahead
- PFI: PowerShares Dynamic Financials Outperforms Its Peers
- Interview with Kevin Carter, AlphaShares CEO
- Report from the Bond War Frontlines
- Full list of Editor's Picks »
- Has Jim Cramer Crossed the Line with Sirius XM? »
- Buffett Takes Berkshire Hathaway on $4 Billion Spending Spree »
- Wall Street Breakfast: Must-Know News »
- Wall Street Breakfast: Must-Know News »
- Wall Street Breakfast: Must-Know News »
- Sirius XM Belt Tightening Begins »
- Sirius XM Shorts Scrambling to Cover »
- No Leadership from Apple Right Now »
- Leave Sirius Alone! »
- AIG and the Lunacy of GAAP Reporting »
- Solarfun Power Holdings Co., Ltd. Q2 2008 Earnings Call Transcript »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Faith Doesn't Cut It - Cramer's Mad Money (8/29/08)
- Again With the Financials - Fast Money Recap (8/29/08)
- Potash One Will Be Top Performer in Agriculture Bull Market
- Luxury Retail Stocks: Two Worth a Look
- 11 Top Canadian Dividend Stocks Available as ADRs
- Natural Gas Is Oversold, and We Are Buying
- Libbey Inc.: The Glass is Half Full
- Mad Money Manual - Cramer's Mad Money (8/28/08)
- An Eye on Gustav - Fast Money Recap (8/28/08)
- Will You Look Back on Today as Your Greatest Missed Opportunity?
- Full list of Long Ideas »
- Priceline: More Headwinds Ahead
- The Option Arm Triplets: Dead Banks Walking
- Short Thesis Still Intact at FirstFed
- Short Story: Lehman
- 'Buy, But Sell' - What Are Analysts Thinking?
- Nordson's Rally Is Over, For Now - Barron's
- What's So Special About RadioShack? - Barron's
- Salesforce.com: It's All About the Guidance
- Three Casino Stocks Rolling Over
- New Web Site For Short Sellers: You Gotta Love Capitalism
- Full list of Short Ideas »
- Faith Doesn't Cut It - Cramer's Mad Money (8/29/08)
- Mad Money Manual - Cramer's Mad Money (8/28/08)
- Diversified Portfolios - Cramer's Mad Money (8/27/08)
- Gustav Moves Overdone - Cramer's Stop Trading! (8/27/08)
- GrafTech is Too Cheap - Cramer's Stop Trading
- The Rebound List - Cramer's Mad Money (8/26/08)
- The List - Cramer's Stop Trading! (8/26/08)
- Can't Turn My Back - Cramer's Lightning Round (8/26/08)
- The Pelosi Factor - Cramer's Mad Money (8/25/08)
- Buy Tech Weakness - Cramer's Lightning Round (8/25/08)
- Full list of Cramers Picks »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »


